

# Let's Talk About Targeted Therapies in Non-Small Cell Lung Cancer



# Roadmap Discussion Guide


This roadmap is an educational tool about treatment pathways for patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC), designed to be used in discussions between healthcare professionals (HCPs) and their patients to facilitate informative and meaningful conversations that will help prepare patients to begin their treatment journeys. Discussion topics include guideline-concordant molecular biomarker testing, as well as recommendations on traditional chemotherapy, chemoimmunotherapy, and oncogene-targeted therapy treatment options for these patients.

Storytelling is an effective way to lead discussions. This roadmap uses the analogy of encountering traffic while driving on a city highway to guide patients with advanced or metastatic NSCLC through treatment

options while they wait for molecular biomarker results. Each mapped route represents a potential treatment pathway that includes key knowledge (guideline recommendations and comparative efficacy and safety of therapies) to better equip patients for success on their respective journeys. To make telling the story easy, the roadmap includes corresponding explanations next to every treatment pathway. There are no “right” answers, only thoughts to help support patients making difficult decisions about a difficult disease.

The accompanying facilitator guide outlines discussion points that can be used by HCPs to help navigate conversations about treatment decisions with patients and to

encourage thoughtful discussion. For the roadmap to enable patients to successfully plan and execute their treatment journey, active participation and discussion are required. Consider the level of communication from each patient when navigating this roadmap and answering questions since some words or phrases may be unfamiliar. Please allow these conversations to grow organically; cancer treatment is a journey, not just a single event, and having several discussions could be more effective to support this journey.



**SCENE:** Three cars encounter a highway traffic jam while driving through the city. They must decide if they will stay on this route and wait for traffic to clear or if they will take an exit to search for a path around the backup.

**STORY:** To a patient, the wait time to receive molecular biomarker results may seem as frustrating as waiting in traffic but with much higher stakes. While cancer journeys may not involve physical travel, they do still require careful thought and planning for success since there are multiple treatment paths that could be taken. Molecular biomarker testing can provide the most appropriate roadmap to navigate treatment options.



**SCENE:** The dark blue car exits the highway and refills on gas before returning to the interstate.

**STORY:** When a driver encounters a traffic jam on a highway, they may be too anxious to wait through it and feel that they need to take action or search for alternate routes. Patients may also feel the need to explore treatment paths that they can begin immediately instead of waiting for biomarker results. For the driver, an urgent need to refuel may lead them to exit to fill up at a nearby gas station before directly returning to their planned route on the highway. Similarly, starting a patient in need of immediate treatment on a round of chemotherapy while waiting for biomarker results could be a compromise on the treatment plan, with minimum impact on the efficacy of potential targeted therapies downstream.



**SCENE:** The light blue car exits the highway and proceeds on a winding path of city street before eventually re-entering from a later entrance ramp.

**STORY:** When a driver encounters a traffic jam on a highway, they may be too anxious to wait through it and feel that they need to take action or search for alternate routes. Patients may also feel the need to explore treatment paths that they can begin immediately instead of waiting for biomarker results. To keep moving, a driver may choose a less direct path through a city with streets that come with their own obstacles, such as construction and traffic lights, which can be as frustrating as waiting in the traffic jam and are not necessarily better routes. It is important to have all of the information before deciding on a route. Discuss what may be the best treatment plan once all the clinical and molecular information about a patient's disease is available. The first-line treatment decision can have long-term impacts and needs to be made carefully.



**SCENE:** The red car stays on the highway to wait through the traffic jam, proceeding directly to Interstate RET 66.

**STORY:** Although it may seem tedious, sometimes waiting for a traffic jam to clear is the fastest and most direct way through. Although molecular biomarker testing may come with a wait, results provide the most appropriate roadmap for navigating treatment. Patients who are positive for an actionable biomarker can be given a targeted therapy, which tends to be better tolerated with better response rates, for a clear path ahead as they navigate their cancer journey.